Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,901–4,000 of 4,628
Treatment of systemic sclerosis-associated interstitial lung disease: a work in progress
Oldham, J. M. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30458-6
A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis
Kolaitis, N. A., & Shah, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00080-9
The Promise (and Pitfalls) of Administrative Data for Idiopathic Pulmonary Fibrosis
Fisher, J. H. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.09.241
Villeneuve, T., Prévôt, G., Lintz, F., Mourin, G., Ferry, G., Bousquet, E., Perelroizen, H., Boghanim, T., Faviez, G., Noël-Savina, É., et al. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/j.rmra.2020.11.055
Tetrandrine modulates SQSTM1-mediated selective autophagy and protects pulmonary fibrosisPreprint
Liu, Y., Zhong, W., Zhang, J., Chen, W., Lu, Y., Qiao, Y., Zeng, Z., Huang, H., Zou, F., Meng, X., et al. (2021) · doi:10.22541/au.161185451.12306983/v1
Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease
Kulkarni, T., Haywood, A., Nambiar, A. M., & South Texas Veterans Health Care System, S. A. (2020) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usprd.2020.5.1.28
ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly
Esendagli, D. R., Shah, U. B., Batıhan, G., Magouliotis, D. E., Meloni, F., Vos, R., Elia, S., & Hellemons, M. E. (2021) · ERJ Open Research · doi:10.1183/23120541.00743-2020
Pulmonary fibrosing diseases: A short review and a therapeutic alternative
Prata, L. O., Queiroz‐Junior, C. M., Rodrigues, C. R., Oliveira, F. M. S., Ferreira, N. J., Rodrigues‐Machado, M. D. G., & Caliari, M. V. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.14.1.0417
Síndrome de Caplan: la paradoja del pulmón como origen de la artritis reumatoide
Rondón-Carvajal, J., & P., J. L. G. (2020) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482020000400341 · Cited by 1
Resultados del primer registro nacional de fibrosis pulmonar idiopática en Chile
P, Á. U., Matías Florenzano, V., Luisa Montecino, L., D., J. C. R., F, M. S., María Angélica Bello, F., M, I. D. L. F., Gino Fuentes, L., Claudio Gallardo, N., Mónica Gutiérrez, C., et al. (2020) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482020000400247
Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?
Assaly, R., Khan, A. R., & Olson, D. E. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0937le
Fisher, J. H. (2017) · TSpace (University of Toronto)
Zheng, Y. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3428
Lang, D., Moazedi‐Fürst, F., Sautner, J., Prosch, H., Handzhiev, S., Hackner, K., Tancevski, I., Flick, H., Koller, H., Kiener, H. P., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01874-3
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
Föll, D., & Kallinich, T. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-60411-3_24-1
Mäkelä, K. (2021) · Työväentutkimus Vuosikirja
Киняйкин, М. Ф., Витальевич, П. Н., Naumova, I. V., Khairzamanova, T., & Fomina, A. V. (2021) · PULMONOLOGIYA · doi:10.18093/0869-0189-2021-31-3-391-396
Clinical Applications of High-Flow Nasal Cannula in Pulmonary Rehabilitation
Poli, B. F., Lastoria, C., & Carlucci, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-42454-1_8
Hoffman, D. B. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Anan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.04.21259968
Ozasa, M., Zaizen, Y., Tabata, K., Kataoka, K., Sato, S., Bychkov, A., Sakamoto, N., Mukae, H., Kondoh, Y., & Fukuoka, J. (2021) · Diagnostics · doi:10.3390/diagnostics11081359
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2021) · Research Square · doi:10.21203/rs.3.rs-729282/v1
Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease
Podolanczuk, A. J., & Martínez, F. J. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00375-1
Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose
Rath, E., Feurstein, J., & Panny, M. (2021) · rheuma plus · doi:10.1007/s12688-021-00470-7
Mechanotherapeutics for the Treatment of Idiopathic Pulmonary Fibrosis
Lagares, D., & Han, H. (2026) · Barcelona Respiratory Network · doi:10.23866/brnrev:2020-0012
Power-lifting influence on the development of motor skills of 12-17 year-old athletes
Михайлович, Г. С. (2009) · Ученые записки университета им. П.Ф. Лесгафта
Can acute exacerbations occurring late after surgery with interstitial lung diseases be predicted?
Ichinokawa, H., Takamochi, K., Nojiri, S., Fukui, M., Hattori, A., Matsunaga, T., & Suzuki, K. (2021) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-021-01707-0 · Cited by 1
Kalinauskaitė-Žukauskė, V. (2021) · Pulmonology and allergology · doi:10.37499/pia.766
Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis
Banudevi, S., & Bose, V. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_12
Poumon sclérodermique, quelles nouveautés ?
Baverez, C., & Sanges, S. (2021) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(21)00656-1 · Cited by 1
Zhou, I. Y., Montesi, S. B., Akam, E. A., & Caravan, P. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00077-6
An Introduction to Advanced Lung Disease
Jablonski, R. P., & Strek, M. E. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_2
Revue des récents essais randomisés dans la sclérodermie systémique
Boleto, G., Avouac, J., & Allanore, Y. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.10.009
Nintedanib bremst Krankheitsprogression über ILD-Subgruppen hinweg
Gesierich, W. (2021) · Pneumo News · doi:10.1007/s15033-021-2759-z
Nintedanib in treating interstitial lung disease associated with systemic scleroderma
Šterclová, M. (2021) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.022
West, A., Chauduri, N., Barczyk, A., WILSHER, M. L., Hopkins, P. M.-A., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3946989
Self-citationTreatment Options for Interstitial Lung disease associated with Connective Tissue Disease
Ehtesham, M., Mahmood, F., Shabbir, M. A., & PEREDO, R. A. (2021) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2021/2.1175
【特集】特発性間質性肺炎の診療の現状と将来展望 特発性肺線維症に対する抗線維化薬の使い方
宏紀, 林., & 安良太, 吾. (2018) · Medical Entomology and Zoology · doi:10.24557/kokyurinsho.2.e00043
持続可能な地域おこしにむけて : 「観光」と「スポーツ」をつなぐ (特集 からだ : スポーツ・教育・科学・文化・芸術からのアプローチ)
大野, 哲. (2013) · Toin University of Yokohama Academic Repository · doi:10.50937/00000564
International Business: What Can We Do?.
Reynolds, J. K. (2002)
Marenghi, M. (2003) · Vignevini: Rivista italiana di viticoltura e di enologia
Experimentos virtuales de Física Mecánica: revisión de libro
Rodríguez, J. O. O. (2011) · Latin American journal of physics education
Alghamdi, D., Kawy, H. S. A., & Damanhouri, Z. A. (2021) · Research Square · doi:10.21203/rs.3.rs-898520/v1
Advances with pharmacotherapy for the treatment of interstitial lung disease
Comes, A., Sgalla, G., Perrotta, A., & Richeldi, L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2016697
Self-citationIdiopathic pulmonary fibrosis in the practice of a family doctor
Skvortsov, V. V., Zadumina, D. N., Skvortsova, E. M., & Tinaeva, E. M. (2022) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2201-05 · Cited by 1
Idiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia
Inutsuka, Y., Yanagihara, T., Matsumoto, K., Yoneda, R., Hashisako, M., Ogo, N., Asoh, T., & Maeyama, T. (2022) · Cureus · doi:10.7759/cureus.20916
“The results of several trials, including the TOMORROW trial and the INPULSIS trial, have shown that nintedanib reduces lung function decline and acute exacerbations in patients with IPF [20,21].”
ResultFainberg, H. P., Oldham, J. M., Molyneaux, P. L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000658
Induced pluripotent stem cells
Calvert, B. A., Lorenzana, Z., Senger, C. N., Hsu, C.-Y., Busch, S. M., Koç-Günel, S., Quiroz, E. J., & Ryan, A. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823882-0.00003-5
Pharmacological Management of Idiopathic Pulmonary Fibrosis
Panahi, L., Udeani, G., Tenpas, A. S., Ofili, T. U., Aguilar, E. M., Burchard, S., Ritenour, A., Chennat, A. J., Ahmed, N., Atphaisit, C., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101390
Grundlagen der medikamentösen Therapie
Drakopanagiotakis, F., & Günther, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-63651-0_5
Idiopathic and Autoimmune Interstitial Lung Disease
Gelbman, B. D., & Crystal, R. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00067-1
The Keys to Making a Confident Diagnosis of IPF
Sheth, J. S., Wadhwa, A., & Flaherty, K. R. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_12
Self-citationAnesthesia for Patients with End-Stage Lung Disease
Costescu, F., & Ma, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-00859-8_31
Role of Progenitors in Pulmonary Fibrosis and Asthma
Banerjee, E. R., & Henderson, W. R. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-16232-4_5
Investigative Approaches to Drug Therapy
Ong, V. H., & Denton, C. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_42
Walsh, S. L. F. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005215
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017 · Cited by 1
Respiratory Organ Aging and Cancer
Witt, L. J., & Presley, C. J. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_63
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Lee, J. S., & Collard, H. R. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_17
Self-citationLung Organoids: A New Pathway into Lung Regeneration and Repair
Tian, L., Zhang, C. C., Rea-Moreno, M., & Chen, Y. (2022) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-93056-1_2
Environmental and Pollution Related Risks for Hypersensitivity Pneumonitis
Ferraro, V., & Morisset, J. (2022) · Respiratory medicine · doi:10.1007/978-3-030-90185-1_5 · Cited by 1
Benefit and clinical characteristics after the use of nintedanib in idiopathic pulmonary fibrosis
Carlos, H.-G. J., Ixel, A. M. E., Enrique, J. A. L., & Andrea, E. A. (2019) · Journal of Lung Pulmonary & Respiratory Research · doi:10.15406/jlprr.2019.06.00202
Understanding and Therapeutically Targeting the Scleroderma Myofibroblast
Ocon, A. J., Lokineni, S., & Korman, B. D. (2022) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00189-8
[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.017 · Cited by 1
Self-citationInterstitielle Lungenerkrankungen
Behr, J. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23814-7.00011-5
Traitement des atteintes systémiques de la maladie de Sjögren
Guern, V. L., & Bécel, G. (2022) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2022.04.004
Markart, P., Drakopanagiotakis, F., Derugin, N., & Wygrecka, M. (2019) · Pneumo News · doi:10.1007/s15033-019-1300-0
Molyneaux, P. L., Nicholson, A. G., Hirani, N., & Wells, A. U. (2020) · doi:10.1093/med/9780198746690.003.0415
Self-citationAcute Exacerbation of Interstitial Lung Disease
(2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52477-3.50082-2
Milger, K., & Behr, J. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10008715
Faculty Opinions recommendation of Mesothelial cells in tissue repair and fibrosis.
Sassoon, D. A., & Valente, M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725707960.793552095
Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Kumar, A., & Hadley, R. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_30
Idiopathic interstitial pneumonias
Aiello, M., Fantin, A., Tzani, P., Chiesa, S., & Olivieri, D. (2019) · European Respiratory Society eBooks · doi:10.1183/9781849840798.024018
Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoïde
Juge, P., & Dieudé, P. (2018) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2018.04.003
Interstitielle Lungenerkrankungen
Behr, J. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-24951-8.00018-x
Interstitielle Lungenerkrankungen
Behr, J. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-24950-1.00028-7
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734825206.793563347
Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Mejía, M. E., & Selman, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2018.09.012
Self-citation(2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.07.008
Patterns of cardiopulmonary response to exercise in fibrotic ILD
Molgat‐Seon, Y., Guenette, J. A., Schaeffer, M. R., Ryerson, C. J., Marillier, M., Vergès, S., O’Donnell, D. E., & Neder, J. A. (2018) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020317 · Cited by 2
Rheumatoid Arthritis Interstitial Lung Disease
Matson, S. M., & Lee, J. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00022-6
New Lung Imaging Findings in Chronic Respiratory Diseases
Ash, S. Y., & Washko, G. R. (2017) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0043
Behr, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_376-1
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R. L., Sköld, C. M., Myllärniemi, M., & Murgia, G. (2019) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2018.140 · Cited by 1
Comprehensive Care of Interstitial Lung Disease
Wijsenbeek, M. S., & Moor, C. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11301-7 · Cited by 1
Elements: in this month's issue
Donnelly, S. C. (2014) · QJM · doi:10.1093/qjmed/hcu133
Healthcare Systems & Policies in Asia (Vol. 20, No. 05, Full Issue)
(2016) · Asia-Pacific Biotech News · doi:10.1142/s021903031600104x
Update zur idiopathischen Lungenfibrose
Jäger-Becker, D. (2018) · Pneumo News · doi:10.1007/s15033-018-1058-9
(2016) · Asia-Pacific Biotech News · doi:10.1142/s0219030316000367
Pulmonary issues in the elderly
Austin, C. A., & Carson, S. S. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.021
Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease
Algamdi, M., Guler, S. A., & Ryerson, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11414-x
Wittman, C., & Swigris, J. J. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_16
Wong, A. W., & Ryerson, C. J. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1722040
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases
Viani, M., Ventura, V., Bianchi, F., et al. (2022) · Biomolecules · doi:10.3390/biom12050717
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Jain, N. K., Jain, S., Mushtaq, H. A., Khedr, A., Koritala, T., Tekin, A., Adhikari, R., Sule, A. A., Gautam, S. C., Pattan, V., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104610 · Cited by 1
Heraganahally, S. S., Howarth, T. P., & Garg, H. (2022) · Nepalese Respiratory Journal · doi:10.3126/nrj.v1i1.45301
Clinical Course of Acute Exacerbation of Fibrosing Interstitial Lung DiseasePreprint
Furuta, K., Fujimoto, D., Matsunashi, A., Morimoto, T., Tanaka, M., Shibaki, R., Shimada, Y., Nagata, K., Tomii, K., & Yamamoto, N. (2022) · Research Square · doi:10.21203/rs.3.rs-1658658/v1
Kohar, K., Andrew, H., & Gabrian, A. (2022) · SCRIPTA SCORE Scientific Medical Journal · doi:10.32734/scripta.v3i2.5390
Antifibrotic therapy and its indications for interstitial pulmonary fibrosis
Doubková, M. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.045
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.